Number of eligible patients: CDEC discussed the uncertainty in the number of people with reasonably critical to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some sufferers who're classified as having moderate or reasonable condition might have a serious bleeding phenoty